Fairmount Funds Management LLC - Mar 28, 2024 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Director, 10%+ Owner
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol
VRDN
Transactions as of
Mar 28, 2024
Transactions value $
$0
Form type
4
Date filed
4/1/2024, 06:32 PM
Previous filing
Feb 16, 2024
Next filing
Apr 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Other -5.86K -100% 0 Mar 28, 2024 Fairmount Healthcare Fund LP F1, F2
transaction VRDN Common Stock Other +5.86K +0.32% 1.85M Mar 28, 2024 Fairmount Healthcare Fund II LP F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Series A Non-Voting Convertible Preferred Stock Other $0 -22K -100% $0.00* 0 Mar 28, 2024 Common Stock 1.47M By Fairmount Healthcare Fund LP F1, F2, F4
transaction VRDN Series A Non-Voting Convertible Preferred Stock Other $0 +22K +19.78% $0.00 133K Mar 28, 2024 Common Stock 1.47M By Fairmount Healthcare Fund II LP F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").
F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F3 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F4 Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.